Eye Care

A panel of pharmacists and doctors explain when a patient should seek professional help for dry eye disease.

Top-line data from the NORSE TWO trial demonstrated that the treatment met the primary and key secondary endpoint for efficacy with clinically impactful change observed for treated patients.

Monazzah Akbar Sarwar, PharmD, continues the conversation for over-the-counter treatment options for patients with dry eye disease.

Brian Walker, RPh, elaborates on the over-the-counter treatment options for patients with dry eye disease.

The panel reflects on the effects COVID-19 has had on their patients with dry eye disease.

A panel of experts discuss how pharmacists can play a role in the nonpharmacologic treatment of dry eye disease.

Lisa M. Nijm, MD, JD, explains dry eye disease and its effects on a suffering patient.

Investigators observed improvements in inflammation of the cornea and ocular itching among patients receiving Verkazia in both trials.

Topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP), found that the study did not meet its primary endpoint of demonstrating a statistically significant improvement in the proportion of treated study eyes.

Case studies include recommendations for eye pain and allergy relief.

Currently, genetic counselors apply their molecular and clinical expertise in diverse roles, many delivered via telehealth.

Patients with this severe condition seem to experience significant differences in quality of life despite having similar visual fields

Four case studies about skin and eye health.

As the nerve exits the eye, the heightened pressure applies mechanical strain to the optic nerve, causing vision loss and potential blindness.

Once accredited for use, the new test will improve doctors’ ability to predict and prevent vision loss from glaucoma.

Over-the-counter products featured in the May 2020 issue.

Pharmacists are in a prime position to convey preventive and treatment options for eyelid inflammation.

In the United States, more than 16 million Americans have DES and that number is expected to increase.

The FDA has approved olopatadine hydrochloride ophthalmic 0.1% and 0.2% solution for sale as an OTC medication in the United States.

Using metformin for type 1 diabetes and handling eye irritation—how would you respond to these cases?

The once-daily solution will be the first once-daily eye-itch allergy-relief drop to be available without a prescription in the United States.

Audible prescription labels will be available in-store at more than 420 Canadian pharmacy locations, including those at Lawtons Drugs, Sobeys, Safeway, Thrifty Foods, Foodland, IGA (western Canada), and FreshCo.

Brolucizumab is the most clinically advanced humanized single-chain antibody fragment. This type of antibody is highly sought after due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics.

Alembic Pharmaceuticals has received FDA approval for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%, therapeutically equivalent to Trusopt Ophthalmic Solution, 2% (Merck Sharp & Dohme Corp.).

Stephanie Conway, PharmD, RPh, Associate Professor at Massachusetts College of Pharmacy & Health Sciences—Worcester/Manchester, discusses best practices for encouraging collaboration between pharmacy and optometry students.